[go: up one dir, main page]

GR3033446T3 - Metalloproteinase inhibitors - Google Patents

Metalloproteinase inhibitors

Info

Publication number
GR3033446T3
GR3033446T3 GR20000401133T GR20000401133T GR3033446T3 GR 3033446 T3 GR3033446 T3 GR 3033446T3 GR 20000401133 T GR20000401133 T GR 20000401133T GR 20000401133 T GR20000401133 T GR 20000401133T GR 3033446 T3 GR3033446 T3 GR 3033446T3
Authority
GR
Greece
Prior art keywords
metalloproteinase inhibitors
compounds
inhibitors
medicine
processes
Prior art date
Application number
GR20000401133T
Other languages
English (en)
Inventor
Andrew Miller
Mark Whittaker
Raymond Paul Beckett
Original Assignee
British Biotech Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9412514A external-priority patent/GB9412514D0/en
Priority claimed from GBGB9506107.3A external-priority patent/GB9506107D0/en
Application filed by British Biotech Pharm filed Critical British Biotech Pharm
Publication of GR3033446T3 publication Critical patent/GR3033446T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GR20000401133T 1994-06-22 2000-05-18 Metalloproteinase inhibitors GR3033446T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9412514A GB9412514D0 (en) 1994-06-22 1994-06-22 Metalloproteinase inhibitors
GBGB9506107.3A GB9506107D0 (en) 1995-03-24 1995-03-24 Metalloproteinase inhibitors
PCT/GB1995/001464 WO1995035275A1 (en) 1994-06-22 1995-06-22 Metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
GR3033446T3 true GR3033446T3 (en) 2000-09-29

Family

ID=26305102

Family Applications (2)

Application Number Title Priority Date Filing Date
GR990402229T GR3031143T3 (en) 1994-06-22 1999-09-02 Metalloproteinase inhibitors
GR20000401133T GR3033446T3 (en) 1994-06-22 2000-05-18 Metalloproteinase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GR990402229T GR3031143T3 (en) 1994-06-22 1999-09-02 Metalloproteinase inhibitors

Country Status (16)

Country Link
US (4) US6022898A (el)
EP (2) EP0766665B1 (el)
JP (2) JPH10507158A (el)
CN (1) CN1151157A (el)
AT (2) ATE182581T1 (el)
AU (2) AU690703B2 (el)
CA (2) CA2193692A1 (el)
DE (2) DE69511089T2 (el)
DK (2) DK0766664T3 (el)
ES (2) ES2133785T3 (el)
GB (2) GB2303850B (el)
GR (2) GR3031143T3 (el)
NO (1) NO965515L (el)
NZ (2) NZ288298A (el)
PT (1) PT766664E (el)
WO (2) WO1995035276A1 (el)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US6380366B1 (en) * 1994-04-28 2002-04-30 Les Laboratoires Aeterna Inc. Shark cartilage extract:process of making, methods of using and compositions thereof
CA2193692A1 (en) * 1994-06-22 1995-12-28 Andrew Miller Metalloproteinase inhibitors
US5817822A (en) * 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
EP0757984B1 (en) * 1995-08-08 2002-10-30 Ono Pharmaceutical Co., Ltd. Hydroxamic acid derivatives useful for inhibiting gelatinase
CA2237590C (en) † 1995-11-13 2011-07-19 Hoechst Aktiengesellschaft Cyclic and heterocyclic n-substituted .alpha.-iminohydroxamic and -carboxylic acids
JP2000502330A (ja) * 1995-12-08 2000-02-29 アグロン・ファーマシュウティカルズ・インコーポレーテッド メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用、ならびにそれらの製造に有用な方法および中間体
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
HU226006B1 (en) * 1996-01-23 2008-02-28 Shionogi & Co Thiophene-sulfonylamino carboxylic and hidroxamic acid derivatives and pharmaceutical compositions with metalloproteinase inhibitory activity containing the same
CA2242416C (en) * 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
US5994351A (en) * 1998-07-27 1999-11-30 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20000011095A (ko) * 1996-05-17 2000-02-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 비페닐술폰아미드 매트릭스 메탈로프로테이나아제 억제제
WO1998006711A1 (en) * 1996-08-16 1998-02-19 Warner-Lambert Company Butyric acid matrix metalloproteinase inhibitors
JP2000501423A (ja) * 1996-08-23 2000-02-08 ファイザー インク． アリールスルホニルアミノヒドロキサム酸誘導体
PL331838A1 (en) * 1996-08-28 1999-08-02 Procter & Gamble 1,3-diheterocyclic inhibitors of metaloproteases
BR9712792A (pt) * 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
CA2264254C (en) * 1996-08-28 2003-03-11 Yetunde Olabisi Taiwo Phosphinic acid amides as matrix metalloprotease inhibitors
TR199900429T2 (xx) * 1996-08-28 1999-05-21 The Procter & Gamble Company Spirosiklik metaloproteaz inhibit�rleri.
JP3347331B2 (ja) * 1996-08-28 2002-11-20 ザ プロクター アンド ギャンブル カンパニー 複素環式メタロプロテアーゼ阻害剤
IL128662A0 (en) * 1996-08-28 2000-01-31 Procter & Gamble Heterocyclic metalloprotease inhibitors
HUP0000641A3 (en) * 1996-10-16 2001-02-28 American Cyanamid Company Madi Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
ATE212619T1 (de) * 1996-10-22 2002-02-15 Upjohn Co Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
WO1998018754A1 (en) 1996-10-28 1998-05-07 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
CN1243507A (zh) * 1997-01-17 2000-02-02 法玛西雅厄普约翰美国公司 用作mmp抑制剂的双磺酰胺异羟肟酸类化合物
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6197791B1 (en) 1997-02-27 2001-03-06 American Cyanamid Company N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
DK0977745T3 (da) * 1997-03-04 2005-03-14 Pharmacia Corp Thioarylsulfonamidhydroxamsyreforbindelser
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP2001521504A (ja) * 1997-04-01 2001-11-06 アグロン・ファーマシュウティカルズ・インコーポレーテッド メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
WO1998050348A1 (en) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DE59802394D1 (de) * 1997-05-09 2002-01-24 Hoechst Ag Substituierte Diaminocarbonsäuren
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
US6300514B1 (en) 1997-06-25 2001-10-09 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
EP1029541B1 (en) 1997-07-22 2006-03-22 Shionogi & Co., Ltd. Therapeutic or prophylactic agent for glomerulopathy
AU746877B2 (en) 1997-07-31 2002-05-02 Procter & Gamble Company, The Acyclic metalloprotease inhibitors
PT895988E (pt) * 1997-08-08 2002-09-30 Pfizer Prod Inc Derivados do acido arilsulfonilamino-hidroxamico
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
GB9801690D0 (en) * 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
CN1195735C (zh) 1998-02-04 2005-04-06 诺瓦提斯公司 抑制使基质退化的金属蛋白酶的磺酰氨基衍生物
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
HRP20000543A2 (en) * 1998-02-19 2001-08-31 American Cyanamid Co N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
GB9810464D0 (en) 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
JP4567886B2 (ja) 1998-07-16 2010-10-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 医薬として使用されるホスフィン酸およびホスホン酸誘導体
US6107337A (en) * 1998-08-06 2000-08-22 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
DE19851184A1 (de) 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
CN1178915C (zh) 1999-01-27 2004-12-08 惠氏控股有限公司 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6506936B1 (en) * 1999-02-25 2003-01-14 Fibrogen, Inc. N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
EP1165530A2 (en) 1999-03-03 2002-01-02 The Procter & Gamble Company Dihetero-substituted metalloprotease inhibitors
NZ513831A (en) 1999-03-03 2001-09-28 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
EP1041072B1 (en) 1999-03-31 2003-07-16 Pfizer Products Inc. Dioxocyclopentyl hydroxamic acids
CN1390215A (zh) 1999-09-10 2003-01-08 麦克公司 酪氨酸激酶抑制剂
US6696456B1 (en) * 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
EP2014285B1 (en) 1999-11-26 2010-05-05 Shionogi&Co., Ltd. NPYY5 antagonists
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
US6465508B1 (en) 2000-02-25 2002-10-15 Wyeth Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
IL151250A0 (en) * 2000-03-21 2003-04-10 Procter & Gamble Difluorobutyric acid metalloprotease inhibitors
RU2002128003A (ru) * 2000-03-21 2004-02-27 Дзе Проктер Энд Гэмбл Компани (US) Ингибиторы металлопротеаз, содержащие карбоциклическую боковую цепь
SK12842002A3 (sk) 2000-03-21 2003-02-04 The Procter And Gamble Company Heterocyklický vedľajší reťazec obsahujúci N-substituované inhibítory metaloproteáz a farmaceutický prípravok s ich obsahom
RU2230736C2 (ru) * 2000-03-21 2004-06-20 Дзе Проктер Энд Гэмбл Компани Содержащие гетероциклическую боковую цепь ингибиторы металлопротеиназы и фармацевтическая композиция
US6495358B1 (en) 2000-04-19 2002-12-17 Wichita State University Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
DE60114022T2 (de) 2000-05-30 2006-07-13 Board Of Governors Of Wayne State University, Detroit Matrix metalloproteinase-inhibitoren
ATE467629T1 (de) * 2001-03-14 2010-05-15 Novartis Pharma Gmbh Azacycloalkyl-substituierte essigsäure-derivate zur verwendung als mmp-inhibitoren
US6884907B2 (en) 2001-05-11 2005-04-26 Guilford Pharmaceuticals Inc. Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
AU2002346053B2 (en) 2001-06-22 2008-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
BR0213736A (pt) 2001-11-01 2004-10-19 Wyeth Corp ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
WO2003104224A1 (en) 2002-06-10 2003-12-18 Pfizer Inc. Metabolites of prinomastat and their sythesis
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
BR0317715A (pt) * 2002-12-27 2005-11-22 Angiotech Int Ag Composições e processos de uso de collajolie
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US7576222B2 (en) * 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
WO2006125208A1 (en) 2005-05-19 2006-11-23 Wayne State University Inhibitors of matrix metalloproteinases
US20110112076A1 (en) * 2008-07-14 2011-05-12 Mcquire Leslie Wighton Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors
WO2011109767A2 (en) 2010-03-04 2011-09-09 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
CA2812362A1 (en) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077998A (en) * 1975-10-28 1978-03-07 Morton-Norwich Products, Inc. Phthaloyl amino acid hydroxamic acids
US4885027A (en) * 1985-04-05 1989-12-05 Chevron Research Company Herbicidal arylmethylenesulfonamido-acetamide and thioacetamide derivatives
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
EP0396596A1 (en) * 1987-12-18 1990-11-14 Schering Corporation Processes and compounds useful for resolving 1-methyl-3-phenylpropylamine
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
DE69108363T2 (de) * 1990-12-03 1995-08-31 Celltech Ltd Peptidylderivate.
US5239113A (en) * 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
CA2193692A1 (en) * 1994-06-22 1995-12-28 Andrew Miller Metalloproteinase inhibitors
US5817822A (en) * 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
KR20000011095A (ko) * 1996-05-17 2000-02-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 비페닐술폰아미드 매트릭스 메탈로프로테이나아제 억제제

Also Published As

Publication number Publication date
ES2145913T3 (es) 2000-07-16
EP0766665B1 (en) 1999-07-28
DE69516143T2 (de) 2000-10-19
AU2746695A (en) 1996-01-15
NZ288299A (en) 1998-06-26
US5962529A (en) 1999-10-05
US6124332A (en) 2000-09-26
GB2303629A (en) 1997-02-26
EP0766665A2 (en) 1997-04-09
GB2303850B (en) 1998-06-10
ES2133785T3 (es) 1999-09-16
GR3031143T3 (en) 1999-12-31
NO965515D0 (no) 1996-12-20
NO965515L (no) 1997-02-20
WO1995035276A1 (en) 1995-12-28
DE69511089T2 (de) 1999-12-16
NZ288298A (en) 1998-12-23
ATE182581T1 (de) 1999-08-15
EP0766664A2 (en) 1997-04-09
CN1151157A (zh) 1997-06-04
GB9623675D0 (en) 1997-01-08
US6022898A (en) 2000-02-08
GB2303629B (en) 1998-09-02
PT766664E (pt) 2000-08-31
CA2193692A1 (en) 1995-12-28
AU2746595A (en) 1996-01-15
GB9623809D0 (en) 1997-01-08
DE69516143D1 (de) 2000-05-11
AU690703B2 (en) 1998-04-30
DK0766665T3 (da) 1999-12-06
CA2193691A1 (en) 1995-12-28
WO1995035275A1 (en) 1995-12-28
JPH10507158A (ja) 1998-07-14
AU695507B2 (en) 1998-08-13
DE69511089D1 (de) 1999-09-02
US6124329A (en) 2000-09-26
ATE191468T1 (de) 2000-04-15
GB2303850A (en) 1997-03-05
JPH10501806A (ja) 1998-02-17
DK0766664T3 (da) 2000-07-31
EP0766664B1 (en) 2000-04-05

Similar Documents

Publication Publication Date Title
GB2303850B (en) Metalloproteinase inhibitors
MY114388A (en) Multiple unit pharmaceutical preparation
UA29450C2 (uk) Похідні гідроксамової кислоти, спосіб їх одержання, спосіб впливу на хвороби та фармацевтична або ветеринарна композиція, що їх містить
MA23170A1 (fr) Procede de preparation d'un nouveau compose .
MX9603520A (es) Derivados del acido hidroxamico y acido carboxilico, procesos para su preparacion y su uso.
NZ285846A (en) Arylsulphonamido-substituted hydroxamic acids and preparation and medicaments useful for inhibiting metalloproteinases
HUP0000641A3 (en) Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
IL139231A0 (en) Preparations for the application of anti-inflammatory, especially antiseptic, agents and/or agents promoting the healing of wounds to the lower respiratory tract
TW324662B (en) Benzamide-containing pharmaceutical composition
RU95113437A (ru) (h±)-сложный этиловый эфир транс-2-диметиламино-1-фенил-3-циклогексентранс-1-карбоновой кислоты в виде первичного ортофосфата и твердая фармацевтическая композиция с обезболивающей активностью
GB9930768D0 (en) Composition
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
RU94040865A (ru) Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
FI965153A0 (fi) Metalloproteinaasi-inhibiittorit
PT742716E (pt) Composicao farmaceutica para administracao transdermica sistemica contendo a substancia activa morfina-6-glucuronido
JO1881B1 (en) Formula II for multi unit disc calibration
ATE109981T1 (de) Therapeutische mittel.
EP0980366A4 (en) ANTITHROMOSIS
MX9503130A (es) Inhibidores de metaloproteinasa, proceso para su preparacion y composiciones farmaceuticas o veterinarias que los contienen.
MY152490A (en) New oral formulation
IT1255678B (it) Composizioni farmaceutiche per la somministrazione di paratormone, suoi frammenti biologicamente attivi o peptidi correlati per via rettale.

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees